The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology

Volumn 75, Issue 4, 2016, Pages 736-739

  Dapavo, Paolo ^a   Vujic, Igor ^b,c   Fierro, Maria Teresa ^a   Quaglino, Pietro ^a   Sanlorenzo, Martina ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Universitatsklinik fur Dermatologie   (Austria)

^c SIGMUND FREUD UNIVERSITY   (Austria)

Author keywords

biosimilar; CT P13; infliximab; psoriasis; Remicade; Remsima

Indexed keywords

BIOSIMILAR AGENT; INFLIXIMAB;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; HUMAN; MALE; MIDDLE AGED; PAIN ASSESSMENT; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; TREATMENT DURATION; VISUAL ANALOG SCALE; COHORT ANALYSIS; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; PSORIASIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOSIMILAR PHARMACEUTICALS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; PSORIASIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84995578185     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.04.068     Document Type: Article

References (13)

1. 1 D'Souza, L.S., Payette, M.J., Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. J Am Acad Dermatol 72:4 (2015), 589–598.
2. 2 Reich, K., Wozel, G., Zheng, H., van Hoogstraten, H.J., Flint, L., Barker, J., Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol 168:6 (2013), 1325–1334.
3. 3 Jung, S.K., Lee, K.H., Jeon, J.W., et al. Physicochemical characterization of Remsima. MAbs 6:5 (2014), 1163–1177.
4. 4 Strober, B.E., Armour, K., Romiti, R., et al. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol 66:2 (2012), 317–322.
5. 5 Yoo, D.H., Racewicz, A., Brzezicki, J., et al. OP0068 A phase 3 randomized controlled trial to compare CT-P13 with infliximab in patients with active rheumatoid arthritis: 54 week results from the PLANETRA study. Ann Rheum Dis, 72(Suppl 3), 2013, A73.
6. 6 Park, W., Hrycaj, P., Jeka, S., et al. A randomized, double-blind, multicenter, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 72 (2013), 1605–1612.
7. 7 European Medicines Agency. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/home/Home_Page.jsp. Accessed February 1, 2016.
8. 8 Beck, A., Reichert, J.M., Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs 5:5 (2013), 621–623.
9. 9 Sieczkowska, J., Jarzębicka, D., Banaszkiewicz, A., et al. Switching between infliximab originator and biosimilar in pediatric patients with inflammatory bowel disease. Preliminary observations. J Crohns Colitis 10:2 (2016), 127–132.
10. 10 Nikiphorou, E., Kautiainen, H., Hannonen, P., et al. Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther 15:12 (2015), 1677–1683.
11. 11 Spertino, J., Lopez-Ferrer, A., Vilarrasa, E., Puig, L., Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions. J Eur Acad Dermatol Venereol 28:11 (2014), 1514–1521.
12. 12 Garcês, S., Demengeot, J., Benito-Garcia, E., The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 72:12 (2013), 1947–1955.
13. 13 Klotz, U., Teml, A., Schwab, M., Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 46:8 (2007), 645–660.